GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Are Embryonic Stem Cells Used in Private Clinics?

Private clinics have given injections described as “embryonic stem cells,” but this does not establish that the cells were genuinely embryonic or that the treatment was approved. A CDC report documented three U.S. residents who developed serious infections after such injections in Mexico in 2022; investigators could not identify the product used.Mm7318a3.htm

For approved treatment, the answer is different: the FDA’s cellular and gene therapy list contains no embryonic stem-cell product.Approved cellular and gene therapy products Approved cord-blood blood-forming cell products are a different cell type, not approval for embryonic stem-cell treatment or for unrelated uses advertised by clinics.Consumer alert regenerative medicine products including stem cells and exosomes In Japan, human embryonic stem cells fall into the highest-risk Class 1 category.000269713.pdf We also checked PMDA’s approved-product list through July 2026 and found no human ES-cell-derived product.000283257.pdf

Are Embryonic Stem Cells Used in Private Clinics?

The practical question is what a clinic proposes to put into your body, for which condition, and under what authorization. A private address, a trial number, or the word “stem” cannot answer those questions.

What embryonic stem cells are

Human embryonic stem cells, often shortened to ES cells or hESCs, are derived from the inner cell mass of a blastocyst, an early embryo. They are pluripotent: they can give rise to the body’s different tissue types. That is not the same as the more limited developmental range of adult mesenchymal stromal cells (MSCs).PMC6390367 Conventional derivation by removing the inner cell mass destroys the embryo; using an established cell line does not mean deriving a new line for each patient.17509209

Cell sources that should not be confused
Cell type Source What the label tells you
Embryonic stem cells (ES cells) Inner cell mass of an early embryo Pluripotent; research products usually contain cells differentiated from an ES-cell line, not a dose of undifferentiated ES cells
Induced pluripotent stem cells (iPS cells) Adult cells reprogrammed to pluripotency Not embryonic cells, even when differentiated into the same target cell type
MSCs Sources include bone marrow, fat, and cord tissue Not pluripotent ES cells; evidence depends on the particular product and use
Cord-blood blood-forming cells Umbilical cord blood Not ES cells; approved products have specific blood-system indications

Cord blood, Wharton’s jelly, amnion, and placenta are not embryonic stem-cell lines. These distinctions matter when comparing different forms of regenerative medicine.

ES-cell trials are not routine clinic care

Human ES-cell-derived treatments are being studied in specialist clinical trials. The four reports below illustrate that research; they are not an exhaustive list or permission for another clinic to sell the same intervention.

Selected early clinical reports, not a pooled assessment of effectiveness
Condition and population Trial Cells and delivery Phase and sample Reported findings and harms Main limits
Adults with moderate Parkinson’s disease; Sweden/UK STEM-PD, NCT05635409 hESC-derived dopamine progenitors, surgically placed in both putamina, deep-brain regions Phase 1/2; 8 participants Seven completed 12-month follow-up. One died from a fungal pulmonary infection with brain involvement while receiving immunosuppression. No serious adverse event was attributed to the cell product.S41591 026 04525 0 Open-label, no control group; primary endpoint was safety, not proven benefit
Adults with Parkinson’s disease; U.S./Canada Bemdaneprocel, NCT04802733 hESC-derived dopamine progenitors, surgically placed in both putamina Phase 1; 12 participants No cell-product-related adverse events at one year; PET imaging supported graft survival at 18 months. One serious seizure was attributed to surgery.S41586 025 08845 y Open-label, no control group; imaging and exploratory improvements do not establish clinical effectiveness
Adults with moderate-to-severe Parkinson’s disease; single center A9-DPC, NCT05887466 hESC-derived dopamine progenitors, surgically placed in both putamina Phase 1/2a; 12 participants Motor scores improved at 12 months; no dose-limiting toxicity or graft-related adverse events were reported.J.cell.2025.09.010 Open-label dose escalation; small sample and short follow-up
Adults with type 1 diabetes and severe hypoglycemia Zimislecel/VX-880, NCT04786262 Stem-cell-derived islet cells, infused into the portal vein Phase 1–2 interim analysis; 14 participants C-peptide, a marker of insulin production, was detected in all 14 after infusion. Serious neutropenia occurred in 3. The paper also reported two deaths: cryptococcal meningitis and progression of preexisting neurocognitive impairment.NEJMoa2506549 All received immunosuppression; the 14-person analysis required at least 12 months of follow-up. Analyses were interim and not prespecified; no control group

All four used immunosuppression. STEM-PD and bemdaneprocel specified a year of it; zimislecel also required an ongoing regimen. “No cell-product-related adverse event” does not mean that surgery, infection, or immune-suppressing drugs were harmless. Nor do these small reports establish long-term safety or a cure.

Why treatment needs specialist care

Donor cells and immune management

An established ES-cell line is not made from your own fat or blood. The studies above used donor-derived cells and immunosuppression. Whether another product needs the same regimen depends on its cells and protocol; donor origin alone does not settle that question. The autologous–allogeneic distinction is only the starting point.

Manufacturing and consent

Ask for the cell-line identity, donor-consent documentation, manufacturing oversight, and product-release tests. For ES-derived products, differentiation into the intended cells and testing for residual undifferentiated cells are important safety checks. ISSCR guidance calls for rigorous oversight and evidence rather than premature sale of unproven interventions.PMC8190668

Other cell products are not substitutes

The FDA’s consumer alert describes products marketed from sources such as fat, cord blood, Wharton’s jelly, and amniotic fluid.Consumer alert regenerative medicine products including stem cells and exosomes Their origin does not make them ES cells, and evidence for one product cannot be transferred to another. Do not assume that such products are exempt from manufacturing requirements or clinical oversight.

iPS cells are another distinct category. PMDA’s list records conditional, time-limited approvals on 6 March 2026 for an iPS-derived heart-muscle sheet and a dopamine-progenitor product.000283257.pdf Those specific approvals are not approvals for ES cells or for unrelated clinic injections. Conditional approval also carries conditions and further evidence requirements.

How to check an embryonic label

A label is a claim to verify, not a laboratory result. In its 2022 commentary, the National Eye Institute warned that clinics can mimic legitimate studies and that a ClinicalTrials.gov entry does not establish FDA authorization.Putting stem cell based therapies context

Questions to ask about the product’s identity
Term in an offer What needs clarification Ask for
“Embryonic stem cells” Genuine human ES-derived cells or a different source? The cell-line name, manufacturing records, product-release information, and authorization for this use
“Cord,” “placental,” or “amniotic” cells These sources are not human ES-cell lines The exact tissue and cell type, processing method, and condition-specific evidence
“Fetal cells” or “live cell therapy” Human fetal tissue, an animal-derived product, or something else? Species, tissue source, consent documentation, and applicable regulatory oversight
“Pluripotent cells” ES cells and iPS cells are different sources Which source, which line, and which differentiated cells will be administered

The Mexico reports show why this matters. The CDC’s 2024 MMWR calls the injections “donor embryonic stem cell injections.”Mm7318a3.htm The 2023 report about the first patient describes “donor umbilical cord stem cells programmed to treat MS.”23 0317_article These are different descriptions. Neither report independently establishes that the injected material was a verified human ES-cell-derived product.

Risks and limits of the evidence

Undifferentiated human ES cells can form teratomas, mixed-tissue tumors, in animal transplantation studies.18620095 That is a manufacturing safety concern, not a measured tumor rate in clinic patients. Removing residual undifferentiated cells reduces a specific concern; it does not establish that a product is safe overall.

Infection is a documented human risk. In the Mexico cluster, isolates from two patients differed by one genetic nucleotide, suggesting a common contaminated source. Investigators suspected the product, reagents, or equipment but could not identify the source; all three patients were still receiving treatment as of 28 March 2024.Mm7318a3.htm

The CDC investigation reported that attempts to identify the product or obtain details of its administration had been unsuccessful.Mm7318a3.htm

The studies also separate cell-product risks from the risks of delivery and immunosuppression. STEM-PD’s fatal fungal infection occurred during active immunosuppression; the bemdaneprocel report recorded a surgery-related seizure.S41591 026 04525 0S41586 025 08845 y A brain graft, portal-vein infusion, joint injection, and intravenous drip are different interventions. Evidence for one cannot establish the safety or benefit of another.

Costs and delayed care matter too. The National Eye Institute cited a Pew review of 360 adverse-event reports, including 20 deaths, across unapproved stem-cell interventions, not specifically ES-cell treatment. These reports do not provide a rate of harm. Its commentary also notes high out-of-pocket costs and the risk of delaying established care.Putting stem cell based therapies context Discuss any proposed treatment with an independent clinician, including whether it could interrupt effective care.

What authorization means

The legal pathway depends on the country and the exact product. Research registration, permission to provide an intervention, and marketing approval are different things.

Authorization checks in selected jurisdictions
Jurisdiction Relevant framework What to verify
United States The checked FDA list contains no ES-cell product. Investigational use requires appropriate FDA oversight, not merely a registry entry. The IND authorization for the particular product and use, the trial protocol, and ethics review; ask about any claimed expanded-access route
Japan ES cells are Class 1 under the regenerative-medicine safety framework; the provision-plan pathway is distinct from product approval under the PMD Act. The actual plan and cell type, certified committee review, MHLW process, and cell-processing arrangements; a Class 2 filing is not a Class 1 plan
European Union EMA/HMA describes central marketing authorization, nationally authorized trials, and specific national hospital exemptions. The product authorization, authorized trial, or national exemption that covers this treatment; a facility certificate alone is insufficient

In the United States, expanded access can sometimes permit investigational treatment outside a trial for a serious or immediately life-threatening condition when no satisfactory alternative exists and other criteria are met. It is not general permission for a clinic to sell an unapproved treatment, and this article does not establish availability of an ES-cell product through that route.Expanded access

PMDA’s framework places Class 1 provision plans under special committee and MHLW/Health Science Council review.000264246.pdf Its December 2023 figures counted seven Class 1 medical-care plans across all included cell categories, not seven ES-cell clinics.000269713.pdf Neither a plan count nor completion of a review demonstrates efficacy. Japan’s regenerative-medicine compliance framework must be checked against the actual intervention, not the clinic’s general claims.

In the EU, EMA/HMA explicitly includes national hospital exemptions alongside authorized products and trials; none is a blanket exemption for private clinics.Unregulated advanced therapy medicinal products pose serious risks health EU trial information is available through the Clinical Trials Information System (CTIS).Euclinicaltrials.eu

Before paying a private clinic

ISSCR advises patients to examine the evidence, risks, and oversight with a trusted medical professional.Nine things to know about stem cell treatments This applies equally when assessing a hospital in Japan or a clinic elsewhere.

Questions to put in writing

  1. Which cells will I receive? Ask for the source, line name, differentiated cell type, and manufacturer.
  2. What authorization covers my condition? Request the product approval, investigational authorization, or provision-plan details, not just a facility certificate.
  3. Does the registry record match the offer? Compare the sponsor, treatment site, cell product, eligibility, and delivery route in ClinicalTrials.gov, jRCT, or CTIS. Ask the regulator or sponsor to clarify discrepancies; registration alone is not authorization.
  4. How was the product tested? Ask about contamination testing, cell identity, and residual undifferentiated cells.
  5. What is the immune-management plan? Ask whether immunosuppression is needed, for how long, who monitors it, and what evidence supports the approach.
  6. What is the evidence for my condition? Ask for the same product, route, patient group, comparison treatment, and follow-up, including serious harms.
  7. Who handles complications? Request the emergency arrangements and follow-up plan, including after returning home. An independent discussion of treatment safety in Japan should address these responsibilities.
  8. What will I pay? Request an itemized treatment-cost estimate for Japan, where applicable, including drugs, monitoring, travel, and complications. Payment does not establish legitimacy or effectiveness.

Warning signs

  • “No risk,” “no side effects,” or guaranteed recovery.
  • “FDA approved” without naming a product and its approved use.
  • “Your own embryonic cells” offered after a simple fat or blood collection.
  • A claimed trial without a matching protocol, sponsor, or authorization.
  • Testimonials replacing evidence for many unrelated diseases.
  • Pressure to pay before receiving consent and complication information.

A practical registry check

For a concrete example, use STEM-PD’s identifier, NCT05635409, rather than searching only “stem cells.” Its published report describes RC17-derived dopamine progenitors placed into both putamina, not a generic intravenous drip.S41591 026 04525 0 If a clinic cites that study for a different product or route, the citation does not support its offer.

The bottom line

There is documented private-clinic use of injections called “embryonic,” but the cell identity and regulatory status must be verified. No human ES-cell-derived product appears in the FDA list checked for this article or PMDA’s list through July 2026.Approved cellular and gene therapy products000283257.pdf Early clinical research is not approval for routine private-clinic care.

Before paying, obtain three things: the exact cell product, the authorization covering your treatment, and a written plan for risks and follow-up. Have a clinician independent of the seller review them. A label or testimonial cannot substitute for those documents.

Considering treatment in Japan and unsure what to ask first?

Use the contact form to send your questions and medical background.

Contact Us

Disclosure: This website offers information and consultation related to treatment in Japan and has a commercial interest in inquiries. This article is not an endorsement of a specific clinic or ES-cell product.

This is general information, not medical advice or a legal opinion. Treatment decisions should be made with a qualified clinician who has reviewed your records. See the site’s medical disclaimer.

How the evidence was checked

This is a document-based review, not clinical experience. We compared regulator lists, published trial reports, and the two different CDC descriptions of the Mexico injections. Key regulatory and safety passages were rechecked on 28 October 2026. PMDA’s list covers approvals through July 2026; its plan counts are historical December 2023 figures. No global census of clinics, patient interviews, site visits, or laboratory confirmation of a clinic’s cells was performed.

References

  1. Nguyen MH, Hasan NA, De Moura VCN, et al. “Notes from the Field: Potential Outbreak of Extrapulmonary Mycobacterium abscessus subspecies massiliense Infections from Stem Cell Treatment Clinics in Mexico — Arizona and Colorado, 2022.” MMWR 2024;73(18):420–422. link. Accessed 23 October 2026.
  2. U.S. Food and Drug Administration. “Approved Cellular and Gene Therapy Products.” Content current as of 17 September 2026. Approved product list. Accessed 28 October 2026.
  3. U.S. Food and Drug Administration. “Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.” 22 July 2020; content current as of 9 April 2024. link. Accessed 28 October 2026.
  4. Pharmaceuticals and Medical Devices Agency (Japan). “Regulatory Update of Regenerative Medicine in Japan.” 27 June 2024. link. Accessed 23 October 2026; relevant evidence rechecked 28 October 2026.
  5. Pharmaceuticals and Medical Devices Agency (Japan). “List of Approved Regenerative Medical Products: April 2015 to July 2026.” Approved product list. Accessed 28 October 2026.
  6. Zakrzewski W, et al. “Stem cells: past, present, and future.” Stem Cell Research & Therapy 2019. link. Accessed 23 October 2026.
  7. Sathananthan H. “Outlook: Derivation of embryonic stem cells for therapy: new technologies.” Reproductive BioMedicine Online 2007;14:635–639. link. Accessed 23 October 2026.
  8. Paul G, Bjartmarz H, Kirkeby A, et al. “Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial.” Nature Medicine 2026;32:3449–3457. link. Accessed 23 October 2026; relevant evidence rechecked 28 October 2026.
  9. Tabar V, Sarva H, Lozano AM, et al. “Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease.” Nature 2025;641:978–983. link. Accessed 23 October 2026; relevant evidence rechecked 28 October 2026.
  10. Chang JW, Na HK, Chang KW, et al. “Phase 1/2a clinical trial of hESC-derived dopamine progenitors in Parkinson’s disease.” Cell 2025;188(25):7036–7048.e11. link. Accessed 23 October 2026; relevant evidence rechecked 28 October 2026.
  11. Reichman TW, Markmann JF, Odorico J, et al. “Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes.” N Engl J Med 2025;393:858–868. Published paper. Accessed 23 October 2026; relevant evidence rechecked 28 October 2026. Abstract: PubMed record 40544428.
  12. ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. Stem Cell Reports 2021;16(6):1398–1408. link. Accessed 23 October 2026.
  13. National Eye Institute. “Putting stem cell-based therapies in context.” 17 November 2022. link. Accessed 23 October 2026; relevant evidence rechecked 28 October 2026.
  14. Wolf AB, Money KM, Chandnani A, et al. “Mycobacterium abscessus Meningitis Associated with Stem Cell Treatment During Medical Tourism.” Emerging Infectious Diseases 2023;29(8):1655–1658. link. Accessed 23 October 2026.
  15. Blum B, Benvenisty N. “The tumorigenicity of human embryonic stem cells.” Advances in Cancer Research 2008;100:133–158. link. Accessed 23 October 2026.
  16. U.S. Food and Drug Administration. “Expanded Access.” Content current as of 22 October 2026. Expanded-access criteria. Accessed 28 October 2026.
  17. Pharmaceuticals and Medical Devices Agency (Japan). “Regulation for Regenerative Medicinal Products.” link. Accessed 23 October 2026.
  18. European Medicines Agency and Heads of Medicines Agencies. “Unregulated advanced therapy medicinal products pose serious risks to health.” 13 March 2025. Patient warning and lawful supply routes. Accessed 28 October 2026.
  19. European Union. Clinical Trials Information System (CTIS). link. Accessed 23 October 2026.
  20. International Society for Stem Cell Research. “9 Things to Know About Stem Cell Treatments.” About Stem Cells patient resource. link. Accessed 28 October 2026.